Berg and the Medical University of South Carolina announced a strategic partnership, designed to identify new therapeutic pathways and potential biomarkers to treat Lupus, the autoimmune disease affecting one in every 2,000 people and one in every 250 young African American women. In the partnership, Berg's Interrogative Biology(TM) platform will be applied to several serum, urine, and kidney data points from select individuals, both lupus patients and controls followed in the Medical University of South Carolina rheumatology clinics. The Berg approach intends to take a holistic, pan-omic approach to drug discovery.

As such the partnership will analyze the disease pathophysiology using the metabolomics, lipidomics, and proteomics data from tissue samples, expanding the search for a biomarker to predict the onset and progression of Lupus.